Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

Blood

Volumn 116, Issue 8, 2010, Pages

  Sánchez Espiridión, Beatriz ^a   Montalbán, Carlos ^b   López, Ángel ^a   Menárguez, Javier ^c   Sabín, Pilar ^c   Ruiz Marcellán, Carmen ^d   Lopez, Andrés ^d   Ramos, Rafael ^e   Rodríguez, Jose ^e   Cánovas, Araceli ^f   Camarero, Carmen ^f   Canales, Miguel ^g   Alves, Javier ^g   Arranz, Reyes ^h   Acevedo, Agustín ^h   Salar, Antonio ⁱ   Serrano, Sergio ⁱ   Bas, Águeda ^j   Moraleda, Jose M ^j   Sánchez Godoy, Pedro ^k   Burgos, Fernando ^k   Rayón, Concepción ^l   Fresno, Manuel F ^l   Laraña, José García ^j   García Cosío, Mónica ^b   Santonja, Carlos ^m   López, Jose L ^m   Llanos, Marta ⁿ   Mollejo, Manuela ^o   Gonzá Lez Carrero, Joaquín ^p   Marín, Ana ^q   Forteza, Jerónimo ^r   García Sanz, Ramón ^s   Tomás, Jose F ^t   Morente, Manuel M ^a   Piris, Miguel A ^a   García, Juan F ^a,t   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^k HOSPITAL SEVERO OCHOA   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m Hospital UniversitarioFundación Jiménez Díaz   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^o HOSPITAL VIRGEN DE LA SALUD   (Spain)

^p HOSPITAL XERAL CÍES   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^r HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^s HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^t MD ANDERSON CANCER CENTER   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PARAFFIN; TUMOR MARKER;

ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HODGKIN DISEASE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956544224     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-270009     Document Type: Article

References (43)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
2. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
3. Moccia AA, Donaldson J, Chhanabhai M, et al. The International Prognostic Project Score (IPS) in advanced-stage Hodgkin lymphoma has limited utility in patients treated in the modern era. Blood. 2009;114(22). Abstract 1554.
4. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia. 2008;22(1):49-58.
5. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100(12):3935-3941.
6. Rassidakis GZ, Medeiros LJ, McDonnell TJ, et al. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res. 2002;8(2):488-493.
7. García JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101(2):681-689. (Pubitemid 36077593)
8. Herling M, Rassidakis GZ, Vassilakopoulos TP, Medeiros LJ, Sarris AH. Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. Blood. 2006;107(3):1240; author reply 1241.
9. Montalbán C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22(9):1664-1673. (Pubitemid 41079805)
10. Sánchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662-668. (Pubitemid 44061368)
11. Sánchez-Espiridión B, Sanchez-Aguilera A, Montalban C, et al. A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res. 2009;15(4):1367-1375.
12. ten Berge RL, Oudejans JJ, Dukers DF, Meijer JW, Ossenkoppele GJ, Meijer CJ. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia. 2001;15(3):458-464.
13. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467-1473. (Pubitemid 40315228)
14. Gloghini A, Canal B, Dal Maso L, Carbone A. Multiple gene expression analyses in human lymphoid tissues by Taqman low-density array using amplified RNA isolated from paraffin-embedded samples. Diagn Mol Pathol. 2009;18(3):156-164.
15. Noutsias M, Rohde M, Block A, et al. Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol Biol. 2008;9:3. (Pubitemid 351330974)
16. Ciotti P, Garuti A, Ballestrero A, et al. Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samples. Diagn Mol Pathol. 2009;18(2):112-118.
17. Li J, Smyth P, Cahill S, et al. Improved RNA quality and TaqMan Pre-amplification method (PreAmp) to enhance expression analysis from formalin fixed paraffin embedded (FFPE) materials. BMC Biotechnol. 2008;8:10. (Pubitemid 351321285)
18. Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics. 2001;17(6):520-525. (Pubitemid 32600498)
19. Solberg HE. Discriminant analysis. CRC Crit Rev Clin Lab Sci. 1978;9(3):209-242.
20. Chu F, Wang L. Applications of support vector machines to cancer classification with microarray data. Int J Neural Syst. 2005;15(6):475-484. (Pubitemid 44099482)
21. Díaz-Uriarte R, Alibes A, Morrissey ER, Canada A, Rueda OM, Neves ML. Asterias: integrated analysis of expression and aCGH data using an open-source, web-based, parallelized software suite. Nucleic Acids Res. 2007;35(Web Server issue):W75-80.
22. Kohlmann M, Held L, Grunert VP. Classification of therapy resistance based on longitudinal biomarker profiles. Biom J. 2009;51(4):610-626.
23. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. (Pubitemid 35461656)
25. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93(2):193-200. (Pubitemid 351397707)
26. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283-4297. (Pubitemid 34627193)
27. Sánchez-Aguilera A, Garcia JF, Sanchez-Beato M, Piris MA. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene. 2006;25(18):2565-2574.
28. Bai M, Papoudou-Bai A, Horianopoulos N, Grepi C, Agnantis NJ, Kanavaros P. Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol. 2007;38(1):103-113. (Pubitemid 44880206)
29. Dürkop H, Hirsch B, Hahn C, Stein H. cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. J Mol Med. 2006;84(2):132-141. (Pubitemid 43201253)
30. Bai M, Tsanou E, Agnantis NJ, et al. Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells. Mod Pathol. 2004;17(11):1338-1345. (Pubitemid 39472988)
31. Wolowiec D, Berger F, Ffrench P, Bryon PA, Ffrench M. CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. Leuk Lymphoma. 1999;35(1-2):147-157. (Pubitemid 29454412)
32. Boss DS, Schwartz GK, Middleton MR, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol. 2010;21(4):884-894.
33. Gilmartin AG, Bleam MR, Richter MC, et al. Distinct concentration- dependent effects of the pololike kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009;69(17):6969-6977.
34. Johnson N, Bentley J, Wang LZ, et al. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer. 2010;102(2):342-350.
35. Jayanthan A, Howard SC, Trippett T, et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009;50(7):1174-1182.
36. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
37. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene. 2002;21(19):3095-3102. (Pubitemid 34522911)
38. Alvaro T, Lejeune M, Camacho FI, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006;91(12):1605-1612. (Pubitemid 46032957)
39. Aldinucci D, Rapana B, Olivo K, et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J Haematol. 2010;148(1):115-118.
40. Valsami S, Pappa V, Rontogianni D, et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica. 2007;92(10):1343-1350. (Pubitemid 350144151)
41. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med. 2000;191(8):1281-1292.
42. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol. 2001;16(2):595-601. (Pubitemid 32297657)
43. Bednarski BK, Baldwin AS Jr, Kim HJ. Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS ONE. 2009;4(9):e6992.